News & Updates

In neonates with congenital diaphragmatic hernia, early treatment with prostacyclin appears to reduce the need for extracorporeal life support in the postnatal period, according to a study.

A lumen-apposing metal stent (LAMS) set with the use of an electrocautery delivery system results in a significant reduction in procedure duration and demonstrates safety and effectiveness in managing symptomatic pancreatic fluid collections (PLCs), reports a study.

Use of antiosteoporotic medication, particularly a long-acting regimen, appears to reduce postfracture mortality, according to a population-based study.

RELIFE, part of the leading Italian Pharmaceutical Company in the world, the Menarini Group, is set to bring a revolutionary approach to dermatology and aesthetic medicine treatments with the new Definisse™ range of facial fillers. The Definisse™ range of hyaluronic acid (HA) fillers boasts a novel, hi-tech stable and elastic 3D matrix developed using innovative EXcellent Three-dimensional Reticulation (XTR™) Technology, allowing good volumizing capability and providing predictable, long-lasting, and safe results. The filler range is now available in India, Singapore, Thailand, and the Philippines, and is set to launch in Malaysia and Indonesia in 2024. The Definisse™ filler range will strengthen Menarini’s existing dermatology and aesthetic portfolio in Asia.

Treatment with the investigational, topical pan-JAK inhibitor delgocitinib cream led to significantly greater improvements in efficacy outcomes compared with the vehicle cream in moderate-to-severe chronic hand eczema (CHE) in the pivotal phase III DELTA 1 trial, offering a rational strategy for targeted therapy.